Biogen Overview
Update this profile
Share Price
$210.63
(As of Friday Closing)
Biogen General Information
Description
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Contact Information
Want to dig into this profile?
We’ll help you find what you need
Learn more
Biogen Stock Performance
(As of Friday Closing)
Stock Price
Previous Close
52 wk Range
Market Cap
Shares
Average Volume
EPS
$210.63
$203.94
$187.16 - $372.12
$30.8B
146M
1.13M
$9.79
Biogen Financials Summary
In Thousands, USD
TTM
31-Mar-2022
FY 2021
31-Dec-2021
FY 2020
31-Dec-2020
FY 2019
31-Dec-2019
EV
34,814,864
40,358,499
41,919,748
55,465,018
Revenue
10,819,500
10,981,700
13,444,600
14,377,900
EBITDA
2,397,900
2,475,500
5,685,200
7,658,000
Net Income
1,449,700
1,556,100
4,000,600
5,888,500
Total Assets
23,614,400
23,877,300
24,618,900
27,234,300
Total Debt
7,587,500
7,603,500
7,828,200
6,367,500
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Biogen Valuation & Funding
Deal Type
Date
Amount
Valuation/ EBITDA
Post-Val
Status
Debt
This information is available in the PitchBook Platform. To explore Biogen‘s full profile, request access.
Request a free trial
Biogen Comparisons
Description
Primary Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer dru
Biotechnology
Cambridge, MA
9,610
As of 2021
000.00
000
0000-00-00
0&0
modo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugi
000000000000000
Cambridge, MA
000
As of 0000
00000
000000000
00000
it esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt
0000 000000000
Bothell, WA
0000
As of 0000
00.000
000000&0
Add Comparison
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trial
Biogen Competitors (22)
Company Name
Financing Status
Location
Employees
Total Raised
Last Financing Date/Type
Last Financing Amount
Ironwood Pharmaceuticals
Formerly VC-backed
Cambridge, MA
000
00000
000000000
00000
000000
Formerly VC-backed
Bothell, WA
0000
00.000
000000&0
000000 00000000
Formerly VC-backed
Foster City, CA
00000
00.000
000000000
00.000
0000000 0000000000
Formerly VC-backed
San Diego, CA
00
00000
000000000
00000
0000000 0000000000
Corporate Backed or Acquired
Allschwil, Switzerland
0000
00.000
00000000
00.000
You’re viewing 5 of 22 competitors. Get the full list »
Biogen Patents
5,225
Total Documents
Applications and Grants
000
Total Patents
Families
206
Granted
39
Pending
000
Expiring
in next 12 mo
Biogen Recent Patent Activity
Publication ID
Patent Title
Status
First Filing Date
Technology (CPC)
Citations
US-20210102939-A1
Assay for jc virus antibodies
Pending
07-Oct-2019
000000000000
CA-3139545-A1
Convergent liquid phase syntheses of oligonucleotides
Pending
08-May-2019
00000000
AU-2020271856-A1
Process for preparing alpha-carboxamide pyrrolidine derivatives
Pending
10-Apr-2019
0000000000
CA-3136536-A1
Process for preparing alpha-carboxamide pyrrolidine derivatives
Pending
10-Apr-2019
0000000000
CA-3136426-A1
Processes for preparing alpha-carboxamide pyrrolidine derivatives
Pending
10-Apr-2019
C07C233/51
To view Biogen’s complete patent history, request access »
Biogen Executive Team (87)
Update this profile
Name
Title
Board Seat
Contact Info
Michel Vounatsos
Chief Executive Officer & Board Member
Michael Mcdonnell
Chief Financial Officer & Executive Vice President
Robin Kramer
Head of Global Business Services and Treasury, Chief Accounting Officer & Senior Vice President
Idan Aharon
Director, Early & External Product Commercialization
Aldemar Degroot Ph.D
Director, External Innovation Lead EU, Canada and Partner Markets
You’re viewing 5 of 87 executive team members. Get the full list »
Biogen Board Members (22)
Name
Representing
Role
Since
Alexander Denner Ph.D
Self
Board Member
000 0000
Brian Posner
Self
Board Member & Chairman of the Compensation and Management Development Committee
000 0000
Caroline Dorsa
Biogen
Board Member & Chairwoman of the Audit Committee
000 0000
Eric Rowinsky MD
Self
Board Member
000 0000
George Scangos Ph.D
Self
Chief Executive Officer & Board Member
000 0000
You’re viewing 5 of 22 board members. Get the full list »
Biogen Signals
Growth Rate
0.80%
Weekly Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trial
Biogen Investors
Investor Name
Investor Type
Holding
Investor Since
Participating Rounds
Contact Info
This information is available in the PitchBook Platform. To explore Biogen‘s full profile, request access.
Request a free trial
Biogen
Investments & Acquisitions (63)
Company Name
Deal Date
Deal Type
Deal Size
Industry
Lead Partner
00000000 0000
11-Jan-2021
00000 0000
00000
Drug Delivery
0000 00000000
31-Dec-2020
0000
00000
Biotechnology
000000 00
000000 000000
06-Oct-2020
00000 0000
0000
Discovery Tools (Healthcare)
000000 000000
22-Sep-2020
0000
00000
Biotechnology
000000 00
Autobahn (Drug Discovery)
09-Jun-2020
Early Stage VC
000.00
Drug Discovery
You’re viewing 5 of 63 investments and acquisitions. Get the full list »
Biogen Exits (30)
Company Name
Exit Date
Exit Type
Exit Size
Status
Buyers
0000000 0000000
01-Nov-2018
000000000 00000000
00000
Completed
00000 00000000000
30-Mar-2017
00000 00000 00
0000
Completed
00000000 000000000
18-Feb-2016
00000 00000 00
0000
Completed
00000 000000000000
06-Jan-2016
00000 00000 00
000.00
Completed
Solid GT
03-Nov-2015
Early Stage VC
000.00
Completed
You’re viewing 5 of 30 exits. Get the full list »